Purchase Option

$ 4400
$ 4000
$ 6000

Celiac Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Celiac Disease Pipeline Drugs Assessment

 

Overview:

Celiac Diseaseis a genetic autoimmune disease. It is caused due to the consumption of protein called gluten, which is found in barley, wheat,and rye. It enables damage the finger-like villi of small intestine and body will be unable to absorb nutrients into thebloodstream that leads to malnutrition. Symptoms of celiac disease include food allergy, watery and itchy eyes, difficulty in breathing, nausea, abdominal pain, mouth ulcers.

Celiac disease is diagnosed by serology tests and genetic tests. Treatment includes strict gluten-free diet. There are no FDA approved drugs to treat celiac disease.

 

Segmentation:

By Drugs, Celiac Disease pipeline drugs are segmented as:

  • Larazotide
  • Pancrelipase
  • Rifaximin
  • Triamcinolone
  • Bupivacaine

By Route of Administration, Celiac Disease pipeline drugs are segmented as:

  • Oral
  • Parenteral

By Trial Phase, Celiac Diseasepipeline drugs are segmented as:

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Company, Celiac Diseasepipeline drugs are segmented as:

  • AMYRA Biotech AG (Switzerland)
  • Avaxia Biologics, Inc. (U.S.)
  • Calypso Biotech SA (Switzerland)
  • Provid Pharmaceuticals Inc. (U.S.)
  • Sitari Pharmaceuticals (U.S.)
  • Cour Pharmaceuticals (U.S.)
  • Glenmark Pharmaceuticals Ltd. (India)
  • Innovate Biopharmaceuticals (U.S.)
  • Others

 

Space Analysis:

  • In November 2017, ImmusanT, Inc.raised $40 million Series C equity financing from ARCH Venture Partners and Vatera Healthcare Partners to proceedPhase II clinical trial of escalating doses of Nexvax2 in celiac patients who possess the human leukocyte antigen DQ2.5 (HLA-DQ2.5) immune recognition gene.
  • In February 2016, Innovate Biopharmaceuticals Inc., completed an agreement to license Alba Therapeutics assets relating to larazotide acetate, a tight junction regulator, progressing toward Phase 3 clinical trials for the treatment of celiac disease.
  • In December 2015, Takeda Pharmaceutical Company Limited and Cour Pharmaceutical Development Company, Inc. entered into a partnership to research and develop novel immune modulating therapies for the potential treatment of celiac disease
  • In March 2015, Falk Pharma and Zedira entered into a collaboration to perform Phase 1 clinical trials of ED1227, a direct-acting inhibitor of tissue transglutaminase. The small molecule targets the dysregulated transglutaminase within the small intestine in order to dampen the immune response to gluten which drives the celiac disease process.

 

Report Description:

Celiac Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Celiac Disease treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Celiac Disease pipeline drugs development. This report studies the dynamics of the Celiac Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Celiac Disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on each drug candidates in the clinical trial phases
 

Location

GEOGRAPHY

PBI Location Map

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
  1. Table of Content
  2. Executive Summary
  3. Global Celiac Disease Pipeline Drugs Assessment Market Introduction
    • Global Celiac Disease Pipeline Drugs Assessment Market – Taxonomy
    • Global Celiac Disease Pipeline Drugs Assessment Market –Definitions
      • Drugs
      • Route of Administration
      • Trial Phase
  1. Global Celiac Disease Pipeline Drugs Assessment Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Celiac Disease Pipeline Drugs Assessment Market Dynamic Factors - Impact Analysis
    • Global Celiac Disease Pipeline Drugs Assessment Market – Competition Landscape
    • Epidemiology
  2. Global Celiac Disease Pipeline Drugs Assessment Market Analysis,2013 - 2017 and Forecast, 2018 – 2024
    • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market OpportunityAnalysis
  3. Global Celiac Disease Pipeline Drugs Assessment Market, By Drugs, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Larazotide
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Pancrelipase
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Rifaximin
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Triamcinolone
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Bupivacaine
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Celiac Disease Pipeline Drugs Assessment Market Forecast, By Route of Administration, 2013 - 2017 and Forecast, 2018 – 2024
    • Oral
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Parenteral
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Celiac Disease Pipeline Drugs Assessment Market Forecast, By Trial Phase, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Preclinical
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 1
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 2
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 3
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 4
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Celiac Disease Pipeline Drugs Assessment Market Forecast, By Region, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • North America
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Celiac Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase, and Region, 2018 – 2024
  2. North America Celiac Disease Pipeline Drugs Assessment MarketAnalysis,2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Drugs Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Larazotide
      • Pancrelipase
      • Rifaximin
      • Triamcinolone
      • Bupivacaine
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Preclinical
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Country Analysis 2016 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • S.
      • Canada
    • North America Celiac Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase, and Country, 2018 – 2024
    • North America Celiac Disease Pipeline Drugs Assessment Market Dynamics – Trends
  3. Europe Celiac Disease Pipeline Drugs Assessment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Drugs Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Larazotide
      • Pancrelipase
      • Rifaximin
      • Triamcinolone
      • Bupivacaine
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Preclinical
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Celiac Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase, and Country, 2018 – 2024
    • Europe Celiac Disease Pipeline Drugs Assessment Market Dynamics – Trends
  4. Asia-Pacific Celiac Disease Pipeline Drugs Assessment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Drugs Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Larazotide
      • Pancrelipase
      • Rifaximin
      • Triamcinolone
      • Bupivacaine
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Preclinical
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Country Analysis2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Japan
      • China
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of Asia-Pacific
    • Asia-Pacific Celiac Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase, and Country, 2018 – 2024
    • Asia-Pacific Celiac Disease Pipeline Drugs Assessment Market Dynamics – Trends
  5. Latin America Celiac Disease Pipeline Drugs Assessment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Drugs Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Larazotide
      • Pancrelipase
      • Rifaximin
      • Triamcinolone
      • Bupivacaine
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Preclinical
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Celiac Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase, and Country, 2018 – 2024
    • Latin America Celiac Disease Pipeline Drugs Assessment Market Dynamics – Trends
  6. Middle East and Africa Celiac Disease Pipeline Drugs Assessment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Drugs Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Larazotide
      • Pancrelipase
      • Rifaximin
      • Triamcinolone
      • Bupivacaine
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Preclinical
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Celiac Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase, and Country, 2018 – 2024
    • MEA Celiac Disease Pipeline Drugs Assessment Market Dynamics – Trends
  7. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Drugs& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • AMYRA Biotech AG (Switzerland)
      • Avaxia Biologics, Inc. (U.S.)
      • Calypso Biotech SA (Switzerland)
      • Provid Pharmaceuticals Inc. (U.S.)
      • Sitari Pharmaceuticals (U.S.)
      • Cour Pharmaceuticals (U.S.)
      • Glenmark Pharmaceuticals Ltd. (India)
      • Innovate Biopharmaceuticals (U.S.)
      • Others
  1. Research Methodology
  2. Key Assumptions and Acronyms

 

  1. Disclaimer
  2. The above mentioned segmentation is tentative; it is changed according to client’s requirement, or research feasibility.

 

  • AMYRA Biotech AG (Switzerland)
  • Avaxia Biologics, Inc. (U.S.)
  • Calypso Biotech SA (Switzerland)
  • Provid Pharmaceuticals Inc. (U.S.)
  • Sitari Pharmaceuticals (U.S.)
  • Cour Pharmaceuticals (U.S.)
  • Glenmark Pharmaceuticals Ltd. (India)
  • Innovate Biopharmaceuticals (U.S.)

Adjacent Markets